» Articles » PMID: 3662471

Altered Pharmacokinetic Disposition of Ciprofloxacin and Vancomycin After Single and Multiple Doses in Rabbits

Overview
Specialty Pharmacology
Date 1987 Jul 1
PMID 3662471
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The pharmacokinetic disposition of vancomycin and ciprofloxacin was assessed in rabbits before the efficacy of these compounds in experimental staphylococcal endocarditis was compared. Ciprofloxacin was given in single intravenous bolus doses of 25 and 35 mg/kg and also in a multiple-dose regimen of 35 mg/kg every 6 h. Vancomycin was given in a similar manner in single doses of 17.5 and 25 mg/kg and in a multiple-dose regimen of 17.5 mg/kg every 6 h. Serum was sampled frequently after injections and analyzed by microbiologic assay for drug concentration. The pharmacokinetic parameters of clearance and steady-state volume of distribution were calculated by compartment-independent methods. These studies revealed that clearance of ciprofloxacin was reduced significantly after multiple doses (7.42 +/- 0.85 [standard deviation] versus 6.09 +/- 0.71 liters/h, P less than 0.01). Although the half-life and volume of distribution increased after multiple dosing, the differences were not statistically significant. The disposition of vancomycin following single doses was significantly altered after the 25-mg/kg dose compared with the 17.5-mg/kg dose. Half-life, clearance, and volume of distribution changed from 1.27 +/- 0.2 to 1.60 +/- 0.21 h (P less than 0.05), 0.54 +/- 0.05 to 0.39 +/- 0.04 liters/h (P less than 0.01), and 0.37 +/- 0.04 to 0.31 +/- 0.03 liters/kg (P less than 0.05), respectively. The disposition of ciprofloxacin was not altered with increases in dose size, and the disposition of vancomycin was not altered after multiple doses. If such alterations in the pharmacokinetic disposition of antimicrobial agents are unanticipated, the higher and more prolonged than expected serum concentrations may have an effect on the outcome of experimental infections.

Citing Articles

Development of Liposomal Ciprofloxacin to Treat Lung Infections.

Cipolla D, Blanchard J, Gonda I Pharmaceutics. 2016; 8(1).

PMID: 26938551 PMC: 4810082. DOI: 10.3390/pharmaceutics8010006.


Disposition kinetics and urinary excretion of ciprofloxacin in goats following single intravenous administration.

Raina R, Prawez S, Dimitrova D, Pankaj N, Verma P J Vet Sci. 2008; 9(3):241-5.

PMID: 18716443 PMC: 2811835. DOI: 10.4142/jvs.2008.9.3.241.


Enhanced elimination of ciprofloxacin after multiple-dose administration of rifampin to rabbits.

Barriere S, Kaatz G, Seo S Antimicrob Agents Chemother. 1989; 33(4):589-90.

PMID: 2729952 PMC: 172487. DOI: 10.1128/AAC.33.4.589.


Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.

Kaatz G, Seo S, Barriere S, Albrecht L, Rybak M Antimicrob Agents Chemother. 1989; 33(4):519-21.

PMID: 2499251 PMC: 172471. DOI: 10.1128/AAC.33.4.519.

References
1.
Sabath L, CASEY J, Ruch P, Stumpf L, FINLAND M . Rapid microassay of gentamicin, kanamycin, neomycin, streptomycin, and vancomycin in serum or plasma. J Lab Clin Med. 1971; 78(3):457-63. View

2.
Carpenter T, Hackbarth C, Chambers H, Sande M . Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus. Antimicrob Agents Chemother. 1986; 30(3):382-4. PMC: 180564. DOI: 10.1128/AAC.30.3.382. View

3.
Reeves D, Bywater M, HOLT H, White L . In-vitro studies with ciprofloxacin, a new 4-quinolone compound. J Antimicrob Chemother. 1984; 13(4):333-46. DOI: 10.1093/jac/13.4.333. View

4.
Aronoff G, Kenner C, SLOAN R, Pottratz S . Multiple-dose ciprofloxacin kinetics in normal subjects. Clin Pharmacol Ther. 1984; 36(3):384-8. DOI: 10.1038/clpt.1984.192. View

5.
Wise R, LOCKLEY R, Webberly M, Dent J . Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob Agents Chemother. 1984; 26(2):208-10. PMC: 284121. DOI: 10.1128/AAC.26.2.208. View